0.0202  0.002 (11.6%)		10-24 14:36
Open: 0.0176 High: 0.0208 Volume: 316,456		Pre. Close: 0.0181 Low: 0.0176 Market Cap: 1(M)

Short term
Mid term
Targets	6-month :	0.02	1-year :	0.03
Resists	First :	0.02	Second :	0.02
Pivot price	0.02
Supports	First :	0.01	Second :	0.01
MAs	MA(5) :	0.01	MA(20) :	0.02
	MA(100) :	0.02	MA(250) :	2.79
MACD	MACD :	-0.1	Signal :	-0.1
%K %D	K(14,3) :	7.4	D(3) :	16.2
RSI	RSI(14): 32
52-week	High :	16.25	Low :	0.01

Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.
[ PTPI ] has closed above bottom band by 5.7%. Bollinger Bands are 39.5% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

If tomorrow:	Open lower	Open higher
High:	0.02 - 0.02	0.02 - 0.02
Low:	0.02 - 0.02	0.02 - 0.02
Close:	0.02 - 0.02	0.02 - 0.02

Petros Pharmaceuticals, Inc., a pharmaceutical company, focuses on men's health therapeutics. The company engages in the commercialization and development of Stendra, an PDE-5 inhibitor prescription medication for the treatment of erectile dysfunction (ED). It also develops and commercializes H100, a patented topical formulation candidate for the treatment of acute Peyronie's disease. The company markets its line of ED products in the form of vacuum erection device products. Petros Pharmaceuticals, Inc. is based in New York, New York.

Wed, 25 Jun 2025
Petros Pharmaceuticals to deconsolidate subsidiary to improve finances - Investing.com

Fri, 20 Jun 2025
Petros Pharmaceuticals Assigns Subsidiary Assets Amid Insolvency - TipRanks

Wed, 21 May 2025
Petros Pharmaceuticals to appeal Nasdaq delisting decision - Investing.com

Wed, 21 May 2025
Petros Pharmaceuticals (PTPI) to Transition from Nasdaq to OTC M - GuruFocus

Wed, 21 May 2025
Petros Pharmaceuticals Announces Transition from NASDAQ to OTC Markets - ACCESS Newswire

Thu, 01 May 2025
Petros Pharmaceuticals Developing First-in-Industry SaaS Platform Utilizing AI and Electronic Health Records Intended to Facilitate Rx-OTC Switches - ACCESS Newswire

Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.	Outperform
Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).	Underperform
Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.	Underperform
Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.	Underperform
Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.	Underperform
Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.	Underperform

Exchange: NASDAQ
Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic
Shares Out	42 (M)
Shares Float	42 (M)
Held by Insiders	0.4 (%)
Held by Institutions	2.9 (%)
Shares Short	494 (K)
Shares Short P.Month	59 (K)

EPS	-57.71
EPS Est Next Qtrly	0
EPS Est This Year	0
EPS Est Next Year	0
Book Value (p.s.)	0.1
Profit Margin	-162.8 %
Operating Margin	-209.4 %
Return on Assets (ttm)	-41.1 %
Return on Equity (ttm)	-268.9 %
Qtrly Rev. Growth	0 %
Gross Profit (p.s.)	0.09
Sales Per Share	0.12
EBITDA (p.s.)	-0.19
Qtrly Earnings Growth	0 %
Operating Cash Flow	-4 (M)
Levered Free Cash Flow	-3 (M)

PE Ratio	-0.01
PEG Ratio	0
Price to Book value	0.17
Price to Sales	0.14
Price to Cash Flow	-0.18

Dividend	0
Forward Dividend	0
Dividend Yield	0%
Dividend Pay Date	Invalid DateTime.
Ex-Dividend Date	Invalid DateTime.